Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial

Original research
by
Jutras-Aswad, Didier et al

Release Date

2022

Geography

Canada

Language of Resource

English

Full Text Available

Yes

Open Access / OK to Reproduce

No

Peer Reviewed

Yes

Objective

The authors aimed to determine whether flexible take-home buprenorphine/naloxone is as effective as supervised methadone in reducing opioid use in prescription-type opioid consumers with opioid use disorder.

Findings/Key points

The buprenorphine/naloxone flexible model of care was safe and noninferior to methadone in reducing opioid use among people with prescription-type opioid use disorder. Participants in the buprenorphine/naloxone group had 0.47 times the odds (95% CI=0.24, 0.90) of being retained in the assigned treatment compared with those in the methadone group.

Design/methods

Seven-site, pan-Canadian, 24-week, pragmatic, open-label, noninferiority, two-arm parallel randomized controlled trial (n=272)

Keywords

Substitution/OAT
About PWUD
Outcomes
Carries/take-home doses